Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Travere Therapeutics, Inc. (TVTX) provides access to the company’s official disclosures as a Nasdaq‑listed biopharmaceutical issuer focused on rare kidney, liver and metabolic diseases. Travere files periodic and current reports with the U.S. Securities and Exchange Commission under the Securities Exchange Act of 1934.
Recent Form 8‑K filings document press releases announcing quarterly and preliminary annual financial results, including net product sales and other financial metrics, as well as broader corporate updates. These reports specify when information is being furnished rather than filed for purposes of Section 18 of the Exchange Act and clarify that such information is not automatically incorporated by reference into registration statements unless expressly stated.
Travere also uses Form 8‑K to report material regulatory developments. For example, the company has filed 8‑Ks describing FDA communications on the supplemental New Drug Application (sNDA) for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS), including the decision that an advisory committee meeting was no longer needed and confirmation of the Prescription Drug User Fee Act (PDUFA) target action date. Another 8‑K notes the FDA’s extension of the review timeline after the company submitted additional information characterized as a Major Amendment.
Through this page, users can review Travere’s financial reporting (10‑K and 10‑Q when available), current reports on significant events (8‑K), and other disclosures that describe the company’s clinical programs, commercial activities, risk factors and capital structure. Stock Titan enhances these filings with AI‑powered summaries that highlight key points in lengthy documents, helping readers quickly understand topics such as revenue drivers, R&D spending, regulatory interactions and forward‑looking statements. Real‑time updates from EDGAR and access to insider and executive transaction reports, when filed on forms such as Form 4, allow investors to monitor how management actions and regulatory events intersect with Travere’s strategy in rare diseases.
Travere Therapeutics, Inc. reported an insider stock transaction by its Chief Financial Officer on 12/01/2025. The CFO exercised an employee stock option to acquire 20,000 shares of common stock at an exercise price of $16.23 per share, then sold 20,000 shares of common stock the same day. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025 and related to an option grant originally made on May 19, 2016.
The weighted average sale price was $35.0101 per share, with individual sale prices ranging from $34.64 to $35.41. Following these transactions, the CFO directly beneficially owned 92,083 shares of Travere Therapeutics common stock.
Travere Therapeutics (TVTX) reported insider activity by its SVP & Chief Accounting Officer on 11/04/2025. The officer exercised multiple employee stock options and sold shares pursuant to a Rule 10b5-1(c) plan adopted on June 10, 2025.
Exercises: 10,000 shares at $25.25; 17,500 at $26.88; 15,000 at $27.50; 12,500 at $22.40; and 6,250 at $8.93. Sale: 67,115 shares at $36. Following these transactions, beneficial ownership stood at 48,545 shares directly.
Travere Therapeutics (TVTX) reported an insider transaction by a director on 10/31/2025. The director exercised options for 8,000 shares at $16.33 and 10,000 shares at $17.44, then sold 18,000 shares at a weighted average price of $35.0334 (range $35.00–$35.15) under a Rule 10b5-1(c) trading plan adopted on June 16, 2025.
Following these transactions, the director beneficially owned 55,500 shares directly. The reported stock options were fully vested and exercisable.
Travere Therapeutics (TVTX) reported an insider transaction by its Chief Commercial Officer. On 10/31/2025, the officer sold 5,591 shares of common stock at $35 per share under a Rule 10b5-1 trading plan adopted on June 16, 2025. On 11/03/2025, the officer made a charitable gift of 1,078 shares to a donor advised fund, also pursuant to the same 10b5-1 plan.
Following these transactions, the officer beneficially owned 117,993 shares, held directly.
Travere Therapeutics (TVTX) reported a strong Q3 2025 turnaround. Total revenue was $164.9 million, up from $62.9 million a year ago, driven by net product sales of $113.2 million and license and collaboration revenue of $51.7 million.
FILSPARI sales reached $90.9 million, while tiopronin products contributed $22.3 million. Collaboration revenue included a $40.0 million market access milestone from CSL Vifor and $9.3 million recognized from the Renalys agreement; royalties from CSL Vifor territories added $2.4 million. Operating income was $24.9 million versus a loss last year, yielding net income of $25.7 million (diluted EPS $0.28).
Cash and cash equivalents were $110.9 million and marketable debt securities were $143.6 million, reflecting repayment of the 2025 notes. Shares outstanding were 89,456,626 as of September 30, 2025. The FDA is reviewing an sNDA for FILSPARI in FSGS with a PDUFA target action date of January 13, 2026; the FDA indicated an advisory committee meeting is no longer needed. Pegtibatinase’s Phase 3 HARMONY enrollment remains paused to finalize manufacturing scale-up, with patients continuing on study medication.
Travere Therapeutics (TVTX) reported insider transactions by its Chief Executive Officer and director under a Rule 10b5-1(c) trading plan adopted on June 16, 2025. On 10/28/2025, the officer exercised 92,872 options at $15.46 and sold 92,872 shares at a weighted average price of $30.379 (range $30.00–$30.97). On 10/29/2025, the officer exercised 27,128 options at $15.46 and sold 27,128 shares at a weighted average price of $30.1192 (range $30.00–$30.48).
Following the reported transactions, the officer beneficially owned 419,173 shares of common stock directly. Derivative securities beneficially owned following the transactions totaled 180,000 options with a $15.46 exercise price expiring on 01/31/2030. The option referenced is fully vested and exercisable.
Travere Therapeutics (TVTX) reported an insider transaction by its Chief Commercial Officer. On 10/28/2025, the officer sold 2,662 shares of common stock at $30 per share (transaction code S), leaving 124,662 shares beneficially owned directly after the sale.
The filing notes the sale was made under a Rule 10b5-1(c) trading plan adopted on June 16, 2025.
Travere Therapeutics (TVTX) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The materials are included as Exhibit 99.1 and are furnished under Item 2.02, meaning they are not deemed filed for Section 18 liability. The company also included Exhibit 104, the cover page iXBRL data file.
Travere’s common stock trades on the Nasdaq Global Market under the symbol TVTX.
Peter Heerma, Chief Commercial Officer of Travere Therapeutics (TVTX), reported a charitable gift of 891 shares of common stock on 09/23/2025. The gift was made to a donor advised fund under a written plan adopted on June 16, 2025 and is described as complying with Rule 10b5-1(c). After the transaction, Heerma beneficially owned 127,324 shares of Travere common stock. The Form 4 was signed by attorney-in-fact Elizabeth E. Reed on 09/24/2025. The filing indicates the transaction was a non-derivative, zero-price disposition (charitable transfer) and does not report any exercise, purchase, or sale for cash.
Elizabeth E. Reed, Chief Legal Officer and General Counsel of Travere Therapeutics (TVTX), reported simultaneous option exercise and sale transactions on 09/22/2025. She exercised an employee stock option to acquire 10,000 shares at an exercise price of $19.08, increasing her direct beneficial ownership to 99,878 shares. On the same date she sold 10,000 shares at an average price of $25.00 under a pre-established Rule 10b5-1 trading plan adopted 06/16/2025; the sold shares relate to an option grant dated 01/04/2017 that expires 01/04/2027. The option was fully vested and exercisable.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
